Mammary stem cells and their regulation by steroid hormones

References

• Clemons M, Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med.344(4), 276–285 (2001).
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res.6(5), 213–218 (2004).
   PubMed Web of Science ®Google Scholar
• Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev.15(1), 17–35 (1993).
   PubMed Web of Science ®Google Scholar
• Parker WH, Broder MS, Chang E et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet. Gynecol.113(5), 1027–1037 (2009).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Chlebowski RT, Hurley P et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol.27(19), 3235–3258 (2009).
   PubMed Web of Science ®Google Scholar
• Marshall SF, Clarke CA, Deapen D et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res.12(1), R4 (2010).
   Google Scholar
• Clarke CA, Glaser SL. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control18(8), 847–852 (2007).
   PubMedGoogle Scholar
• Schedin P. Pregnancy-associated breast cancer and metastasis. Nat. Rev. Cancer6(4), 281–291 (2006).
   PubMed Web of Science ®Google Scholar
• Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res.8(4), R43 (2006).
   PubMedGoogle Scholar
• Stingl J, Eirew P, Ricketson I et al. Purification and unique properties of mammary epithelial stem cells. Nature439, 993–997 (2006).
   PubMed Web of Science ®Google Scholar
• Shackleton M, Vaillant F, Simpson KJ et al. Generation of a functional mammary gland from a single stem cell. Nature439(7072), 84–88 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J. Mammary Gland Biol. Neoplasia9(1), 3–13 (2004).
   PubMed Web of Science ®Google Scholar
• Korach KS, Couse JF, Curtis SW et al. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog. Horm. Res.51, 159–186; discussion 186–158 (1996).
   PubMedGoogle Scholar
• Walden PD, Ruan W, Feldman M, Kleinberg DL. Evidence that the mammary fat pad mediates the action of growth hormone in mammary gland development. Endocrinology139(2), 659–662 (1998).
   PubMedGoogle Scholar
• Gallego MI, Binart N, Robinson GW et al. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev. Biol.229(1), 163–175 (2001).
   PubMed Web of Science ®Google Scholar
• Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology137(1), 321–330 (1996).
   PubMedGoogle Scholar
• Xie W, Paterson AJ, Chin E, Nabell LM, Kudlow JE. Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. Mol. Endocrinol.11(12), 1766–1781 (1997).
   PubMedGoogle Scholar
• Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development126(2), 335–344 (1999).
   PubMed Web of Science ®Google Scholar
• Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary Gland Biol. Neoplasia2(4), 323–334 (1997).
   PubMed Web of Science ®Google Scholar
• Mueller SO, Clark JA, Myers PH, Korach KS. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor α. Endocrinology143(6), 2357–2365 (2002).
   PubMed Web of Science ®Google Scholar
• Lydon JP, DeMayo FJ, Funk CR et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev.9(18), 2266–2278 (1995).
   PubMed Web of Science ®Google Scholar
• Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat. Rev. Cancer3(11), 832–844 (2003).
   PubMed Web of Science ®Google Scholar
• Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L et al. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol.177(1), 87–101 (2007).
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Natl Acad. Sci. USA100(17), 9744–9749 (2003).
   PubMed Web of Science ®Google Scholar
• Brisken C, Park S, Vass T, Lydon JP, O’Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc. Natl Acad. Sci. USA95(9), 5076–5081 (1998).
   PubMed Web of Science ®Google Scholar
• Neville MC, Morton J, Umemura S. Lactogenesis. The transition from pregnancy to lactation. Pediatr. Clin. North Am.48(1), 35–52 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res.57(22), 4987–4991 (1997).
   PubMed Web of Science ®Google Scholar
• Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat53(3), 217–227 (1999).
   PubMed Web of Science ®Google Scholar
• Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor α is required for proliferation and morphogenesis in the mammary gland. Proc. Natl Acad. Sci. USA103(7), 2196–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Beleut M, Rajaram RD, Caikovski M et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl Acad. Sci. USA107(7), 2989–2994 (2010).
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Soyal SM, Li J et al. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. FASEB J.24(11), 4408–4419 (2010).
   PubMed Web of Science ®Google Scholar
• Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev.23(22), 2563–2577 (2009).
   PubMed Web of Science ®Google Scholar
• Smith GH, Medina D. A morphologically distinct candidate for an epithelial stem cell in mouse mammary gland. J. Cell Sci.90(Pt 1), 173–183 (1988).
   PubMedGoogle Scholar
• Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J. Cell Biol.176, 19–26 (2007).
   PubMedGoogle Scholar
• Asselin-Labat ML, Sutherland KD, Barker H et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol.9(2), 201–209 (2007).
   PubMed Web of Science ®Google Scholar
• Asselin-Labat ML, Vaillant F, Shackleton M, Bouras T, Lindeman GJ, Visvader JE. Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harb. Symp. Quant. Biol.73, 469–478 (2008).
   PubMedGoogle Scholar
• Bouras T, Pal B, Vaillant F et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell3(4), 429–441 (2008).
   PubMed Web of Science ®Google Scholar
• Stingl J, Eaves CJ, Kuusk U, Emerman JT. Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation63(4), 201–213 (1998).
   PubMed Web of Science ®Google Scholar
• Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res. Treat67(2), 93–109 (2001).
   PubMed Web of Science ®Google Scholar
• Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev.16(6), 693–706 (2002).
   PubMed Web of Science ®Google Scholar
• Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev.17(10), 1253–1270 (2003).
   PubMed Web of Science ®Google Scholar
• Kuperwasser C, Chavarria T, Wu M et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA101(14), 4966–4971 (2004).
   PubMed Web of Science ®Google Scholar
• Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med.15(8), 907–913 (2009).
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell1(5), 555–567 (2007).
   PubMed Web of Science ®Google Scholar
• Eirew P, Stingl J, Raouf A et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat. Med.14(12), 1384–1389 (2008).
   PubMed Web of Science ®Google Scholar
• Booth BW, Smith GH. Estrogen receptor-α and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res.8(4), R49 (2006).
   PubMed Web of Science ®Google Scholar
• Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol.277(2), 443–456 (2005).
   PubMed Web of Science ®Google Scholar
• Asselin-Labat ML, Shackleton M, Stingl J et al. Steroid hormone receptor status of mouse mammary stem cells. J. Natl Cancer Inst.98(14), 1011–1014 (2006).
   PubMedGoogle Scholar
• Lim E, Wu D, Pal B et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res.12(2), R21 (2010).
   PubMedGoogle Scholar
• Joshi PA, Jackson HW, Beristain AG et al. Progesterone induces adult mammary stem cell expansion. Nature465(7299), 803–807 (2010).
   PubMed Web of Science ®Google Scholar
• Asselin-Labat ML, Vaillant F, Sheridan JM et al. Control of mammary stem cell function by steroid hormone signalling. Nature465(7299), 798–802 (2010).
   PubMed Web of Science ®Google Scholar
• Navarrete MA, Maier CM, Falzoni R et al. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res.7(3), R306–R313 (2005).
   PubMed Web of Science ®Google Scholar
• Graham JD, Mote PA, Salagame U et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology150(7), 3318–3326 (2009).
   PubMed Web of Science ®Google Scholar
• Howell A, Dowsett M. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res.6(6), 269–274 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc. Natl Acad. Sci. USA95(12), 6965–6970 (1998).
   PubMed Web of Science ®Google Scholar
• Ciarloni L, Mallepell S, Brisken C. Amphiregulin is an essential mediator of estrogen receptor α function in mammary gland development. Proc. Natl Acad. Sci. USA104(13), 5455–5460 (2007).
   PubMedGoogle Scholar
• Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development132(17), 3923–3933 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez-Valdivia R, Mukherjee A, Creighton CJ et al. Transcriptional response of the murine mammary gland to acute progesterone exposure. Endocrinology149(12), 6236–6250 (2008).
   PubMed Web of Science ®Google Scholar
• Srivastava S, Matsuda M, Hou Z et al. Receptor activator of NF-κB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J. Biol. Chem.278(46), 46171–46178 (2003).
   PubMedGoogle Scholar
• Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh H, Blumberg H, Dougall WC. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell Biol.27(4), 1442–1454 (2007).
   PubMed Web of Science ®Google Scholar
• Fata JE, Kong YY, Li J et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell103(1), 41–50 (2000).
   PubMed Web of Science ®Google Scholar
• Fernandez-Valdivia R, Mukherjee A, Ying Y et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol.328(1), 127–139 (2009).
   PubMed Web of Science ®Google Scholar
• Kim NS, Kim HJ, Koo BK et al. Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol. Cell Biol.26(3), 1002–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature468(7320), 98–102 (2010).
   PubMed Web of Science ®Google Scholar
• Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology147(9), 4010–4021 (2006).
   PubMed Web of Science ®Google Scholar
• Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc. Natl Acad. Sci. USA96(5), 2520–2525 (1999).
   PubMed Web of Science ®Google Scholar
• Medina D, Smith GH. Chemical carcinogen-induced tumorigenesis in parous, involuted mouse mammary glands. J. Natl Cancer Inst.91(11), 967–969 (1999).
   PubMedGoogle Scholar
• D’Cruz CM, Moody SE, Master SR et al. Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland. Mol. Endocrinol.16(9), 2034–2051 (2002).
   PubMed Web of Science ®Google Scholar
• Master SR, Chodosh LA. Evolving views of involution. Breast Cancer Res.6(2), 89–92 (2004).
   PubMedGoogle Scholar
• Matulka LA, Triplett AA, Wagner KU. Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev. Biol.303(1), 29–44 (2007).
   PubMedGoogle Scholar
• Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-β1 expression. Oncogene24(4), 552–560 (2005).
   PubMedGoogle Scholar
• Ginger MR, Gonzalez-Rimbau MF, Gay JP, Rosen JM. Persistent changes in gene expression induced by estrogen and progesterone in the rat mammary gland. Mol. Endocrinol.15(11), 1993–2009 (2001).
   PubMed Web of Science ®Google Scholar
• Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocr. Relat. Cancer14(4), 907–933 (2007).
   PubMed Web of Science ®Google Scholar
• Britt KL, Kendrick H, Regan JL et al. Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells. Breast Cancer Res.11(2), R20 (2009).
   Google Scholar
• Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li Y. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells – implications for pregnancy-induced protection against breast cancer. Stem Cells26(12), 3205–3209 (2008).
   PubMedGoogle Scholar
• Smith GH. Stem cells and mammary cancer in mice. Stem Cell Rev.1(3), 215–223 (2005).
   PubMedGoogle Scholar
• Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res.68(19), 7711–7717 (2008).
   PubMed Web of Science ®Google Scholar
• Li Y, Welm B, Podsypanina K et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl Acad. Sci. USA100(26), 15853–15858 (2003).
   PubMed Web of Science ®Google Scholar
• Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA101(12), 4158–4163 (2004).
   PubMed Web of Science ®Google Scholar
• Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA104(2), 618–623 (2007).
   PubMed Web of Science ®Google Scholar
• Cicalese A, Bonizzi G, Pasi CE et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell138(6), 1083–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Hewitt SC, Bocchinfuso WP, Zhai J et al. Lack of ductal development in the absence of functional estrogen receptor α delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res.62(10), 2798–2805 (2002).
   PubMedGoogle Scholar
• Lydon JP, Ge G, Kittrell FS, Medina D, O’Malley BW. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res.59(17), 4276–4284 (1999).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Jacob AP, Jones J et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature468(7320), 103–107 (2010).
   PubMed Web of Science ®Google Scholar
• Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA104(29), 12111–12116 (2007).
   PubMed Web of Science ®Google Scholar
• Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl Acad. Sci. USA98(17), 9587–9592 (2001).
   PubMed Web of Science ®Google Scholar
• Ma Y, Katiyar P, Jones LP et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol.20(1), 14–34 (2006).
   PubMed Web of Science ®Google Scholar
• Fan S, Wang J, Yuan R et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science284(5418), 1354–1356 (1999).
   PubMed Web of Science ®Google Scholar
• Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science314(5804), 1467–1470 (2006).
   PubMed Web of Science ®Google Scholar
• Molyneux G, Geyer FC, Magnay FA et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell7(3), 403–417 (2010).
   PubMedGoogle Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst.97(22), 1652–1662 (2005).
   PubMed Web of Science ®Google Scholar
• King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA286(18), 2251–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet356(9245), 1876–1881 (2000).
   PubMed Web of Science ®Google Scholar
• Fornier MN. Denosumab: second chapter in controlling bone metastases or a new book? J. Clin. Oncol.28(35), 5127–5131 (2010).
   PubMedGoogle Scholar